EntreMed, Inc. (NASDAQ:ENMD)
Download PDF 
Symbol: NASDAQ: ENMD
Address:
EntreMed, Inc.
9640 Medical Center Drive
Rockville, MD 20850
(240) 864-2600
www.entremed.com
Top Investment Highlights
- Company develops multi-mechanism drugs for the treatment of cancer and
inflammatory diseases.
- Two of its product candidates are in Phase II clinical trials for cancer, with several
others closely following in Phase I and pre-clinical development.
- Because its products work through multiple mechanisms of action, greater economic
potential may be possible due to its offering of several therapeutic applications.
- Company has strong intellectual property rights, and owns or has licensed on an
exclusive basis a total of 49 issued patents and patent applications in the US for its
product candidates.
Company Overview
EntreMed, Inc. is a clinical-stage pharmaceutical
company focused on developing
next generation multi-mechanism
drugs for use in oncology, a medical field
that studies the diagnosis, treatment, and
prevention of cancer. The company’s
product candidates target both diseased
cells and the blood vessels that nourish
them. EntreMed is focused on developing
drugs that are safe, convenient, and
provide the potential for improved
patient outcomes. The company’s goal is
to develop and commercialize therapeutics
based on its expertise in angiogenesis,
cell cycle regulation, and inflammation.
These are all processes vital to the
progression of cancer and other diseases,
and are the focus of the company’s
three clinical product candidates.
Clinical trials have enabled the company
to identify new molecules and chemical
entities that represent important targets
in the treatment of cancer and inflammatory
diseases.
The company is developing compounds
that have broad therapeutic and commercial
potential in oncology. To further
advance its commercial objectives, the
company will seek strategic alliances,
licensing relationships, and co-development
partnerships.
Product Candidates
The treatment of cancer is multifaceted,
often requiring a combination of
surgery, chemotherapy, radiotherapy, and
palliative care. It has become increasingly
clear to the scientific community that its
treatment must match the complexity of
this disease by attacking cancerous cells
through a diversity of pathways.
EntreMed’s compounds work through
multiple mechanisms of action (MOA),
meaning a single compound can attack a
disease through multiple cellular pathways
and even impact different diseases.
The company developed its initial drug
pipeline based on comprehensive
research into the relationship between
malignancy and angiogenesis (the growth
of new blood vessels).
One of EntreMed’s lead drug candidates,
Panzem® (2-methoxyestradiol or
2ME2) NCD, is currently being tested as
a cancer therapeutic in five Phase 2 clinical
trials and has been granted FDA designation
in three cancer indications –
including glioblastoma multiforme, multiple
myeloma and ovarian cancer.
Panzem® NCD has the potential to
work through multiple mechanisms of
action to attack cancer cells through
multiple pathways that affect the formation
and replication of tumor cells, and
can interrupt the formation of blood
vessels that nourish tumor cells and sustain
tumor growth.
The company’s second lead drug candidate,
MKC-1, is a novel cell cycle
inhibitor currently in Phase 1 and 2
clinical trials for cancer. In May 2006,
the company commenced clinical studies
with its third clinical-stage compound,
ENMD-1198, in patients with
advanced cancer.
EntreMed is developing drug candidates
that will be easy to use, with minimal
interruption to the patient’s daily
routine, as compared to other modes of
drug administration. Its main focus is on
oral drug delivery technologies and other
administration routes.
Intellectual Property
All EntreMed pipeline programs are
backed by strong intellectual property
rights. Each product candidate is covered
by issued or pending composition,
method, and use patents. The company
owns, or has licensed on an exclusive
basis, a total of 49 issued patents and
patent applications in the US for its
product candidates. EntreMed has a total
of 136 issued patents and pending
patent applications in the US and other
countries.
Economic Viability
The company’s current focus on the
development of small molecule, multiple
mechanism drug candidates may translate
into lower product development,
process development, and other associated
costs when compared to biological
products. Alternatively, greater economic
potential may be possible because each
of EntreMed’s compounds may offer
several therapeutic applications.
Business Development
Although oncology is EntreMed’s principal
clinical and commercial focus, recent
data supports further development of its
compounds in non-oncology applications
as well (i.e. rheumatoid arthritis).
The company will move forward, continuing
to develop compounds for oncology
and inflammatory diseases, while
selectively exploring strategic alliances
for its compounds in other therapeutic
areas. EntreMed may also pursue codevelopment
partners for its core
pipeline product candidates to help
accelerate their development and
strengthen the development programs.
In turn, the company can provide its codevelopment
partners with substantial
know-how relating to small molecules
and peptides that inhibit processes like
angiogenesis and inflammation.
Financial
As of December 31, 2006, EntreMed
reported cash and short-term investments
of approximately $50.6 million.
Total expenses for 2006 were in line with
its Phase II progress on Panzem® NCD
and MKC-1, as well as its Phase I activity
with ENMD-1198. The company has
cash and short-term investments to support
current and planned operations into
the second half of 2008.
Management
EntreMed’s management team has
aligned the company’s core scientific
strengths and is executing a focused
business strategy, while also maintaining
prudent resource management and fiscal
responsibility and accountability.
EntreMed’s senior management team
consists of James S. Burns, President
and Chief Executive Officer; Dane
Saglio, Chief Financial Officer; Carolyn
F. Sidor, M.D., M.B.A, Vice President
and Chief Medical Officer; Marc
Corrado, J.D., Vice President, Corporate
Development; and Cynthia Wong Hu,
J.D., Vice President, General Counsel,
and Secretary.
This corporate profile is based upon information provided
by management of EntreMed, Inc. The information
is not intended to be and shall not constitute, an offer
to sell or solicitation of any offer to buy any security. It
is intended for information only and to increase
awareness of EntreMed, Inc. services.
Safe Harbor Statement: The statements in this document
relating to future product availability, collaboration
and partnership and positive direction are forward-
looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Some
or all of the aspects anticipated by these forward-looking
statements may not, in fact, occur. Factors that
could cause or contribute to such differences include,
but are not limited to, contractual difficulties, demand
for EntreMed, Inc. products, the future market price of
EntreMed, Inc. common stock and the Company’s ability
to obtain necessary future financing. EQUITIES
Magazine was paid by EntreMed, Inc. to write and
print this profile. Before investing in any security, you
are strongly advised to review all public filings of the
issuer of such security, which can be found at
www.sec.gov, as well as the warnings published by
the Securities and Exchange Commission at
www.sec.gov/investor.shtml.
